Nebivolol Accord (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebivolol Accord, is a beta‑blocker presented as an oral tablet for oral use. It is indicated for the management of hypertension in adult patients, helping to lower elevated blood pressure and reduce cardiovascular risk.

GNH USA supplies Nebivolol Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality, regulatory compliance and reliable logistics for timely global delivery.

Nebivolol is a selective beta‑1 blocker used primarily in the cardiovascular therapeutic pathway to control blood pressure and support heart function. - Hypertension: lowers systolic and diastolic blood pressure in adult patients. - Chronic heart failure: improves ventricular function and may reduce mortality when added to standard therapy. - Age‑related systolic hypertension: provides better blood pressure control in older adults.

Nebivolol is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate pain often transient. - Dizziness or light‑headedness: especially on standing. - Fatigue or tiredness: reduced energy levels. - Nausea or abdominal discomfort. - Bradycardia: slower than normal heart rate. - Peripheral edema: mild swelling of ankles or feet.

Serious or Rare Side Effects: - Severe bradycardia: markedly low heart rate requiring medical attention. - Symptomatic hypotension: sudden drop in blood pressure causing faintness. - Heart block or atrioventricular conduction disturbances. - Bronchospasm: difficulty breathing, particularly in patients with asthma. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Depression or mood changes: rare but reported.

Before initiating therapy, clinicians should consider several safety factors. - Blood pressure monitoring: ensure adequate control and avoid excessive drops. - Cardiac assessment: evaluate heart rate and conduction abnormalities. - Respiratory caution: avoid use in patients with severe asthma or COPD. - Diabetes management: monitor glucose as beta‑blockers may mask hypoglycaemia symptoms. - Discontinuation: taper gradually to prevent rebound hypertension. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Nebivolol may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Other beta‑blockers: additive bradycardia and hypotension. - Calcium‑channel blockers (verapamil, diltiazem): increased risk of heart block. - Strong CYP2D6 inhibitors (paroxetine, fluoxetine): elevated nebivolol plasma levels.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance antihypertensive effect, monitor electrolytes. - ACE inhibitors or ARBs: combined effect on blood pressure, watch for hypotension. - NSAIDs: may reduce antihypertensive efficacy. - Antidiabetic agents: possible masking of hypoglycaemia symptoms.